Lindsey Rolfe
Direttore/Membro del Consiglio presso ATRECA, INC.
Patrimonio netto: - $ in data 30/04/2024
Posizioni attive di Lindsey Rolfe
Società | Posizione | Inizio | Fine |
---|---|---|---|
ATRECA, INC. | Direttore/Membro del Consiglio | 22/08/2019 | - |
Independent Dir/Board Member | 22/08/2019 | - | |
The Royal College of Physicians | Corporate Officer/Principal | - | - |
Storia della carriera di Lindsey Rolfe
Precedenti posizioni note di Lindsey Rolfe
Società | Posizione | Inizio | Fine |
---|---|---|---|
CLOVIS ONCOLOGY, INC. | Direttore Tecnico/Scientifico/R&S | 01/08/2015 | 01/06/2023 |
Corporate Officer/Principal | 01/04/2010 | 01/08/2015 |
Formazione di Lindsey Rolfe
The University of Edinburgh | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 3 |
Regno Unito | 3 |
Posizioni
Director/Board Member | 2 |
Corporate Officer/Principal | 2 |
Independent Dir/Board Member | 2 |
Settori
Health Technology | 3 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ATRECA, INC. | Health Technology |
Aziende private | 1 |
---|---|
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
- Borsa valori
- Insiders
- Lindsey Rolfe
- Esperienza